Chronic Lymphocytic Leukemia | Specialty

Ibrutinib for CLL with Deletion 17p

January 13th 2017

Managing Ibrutinib Toxicity in CLL

January 13th 2017

Sequencing Therapies for Relapsed/Refractory CLL

January 13th 2017

The Role of Maintenance Therapy in CLL

January 13th 2017

CLL Risk Stratification and Treatment Approach

January 13th 2017

Chronic Lymphocytic Leukemia; Initiating Therapy

January 13th 2017

Emerging Therapies for Follicular Lymphoma

January 13th 2017

R2-CHOP for Relapsed Follicular Lymphoma

January 13th 2017

Sequencing Therapies for Follicular Lymphoma

January 13th 2017

Follicular Lymphoma: Consolidation and Maintenance

January 13th 2017

Follicular Lymphoma; Triggers to Initiate Therapy

January 13th 2017

Expert Discusses "Sequential Triple-T" Trials in CLL

January 4th 2017

In the treatment paradigm of chronic lymphocytic leukemia, anti-CD20 antibodies such as obinutuzumab, and other targeted agents like ibrutinib, have shown promising efficacy and tolerability when compared with standard chemoimmunotherapy.

Dr. Zelenetz on Treatment for Patients With CLL Who Fail on Ibrutinib or Idelalisib

January 4th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia who fail on ibrutinib or idelalisib.

Evolution Anticipated in First-Line Treatment for CLL, Indolent Lymphomas

January 3rd 2017

Novel therapies are being investigated in 2 areas of hematologic malignancies, but the first-line setting is where the brunt of research needs to be conducted.

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL

December 22nd 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.

EC Approves Ofatumumab Combo in Relapsed CLL

December 13th 2016

The European Commission has approved ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for adult patients with relapsed chronic lymphocytic leukemia.

High Response Rate With Venetoclax in Relapsed/Refractory CLL

December 8th 2016

Two thirds of patients with chronic lymphocytic leukemia (CLL) that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax, results of a small open-label trial showed.

Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL

December 7th 2016

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.

BGB-3111 Response Rate Nears 100% in CLL/SLL

December 6th 2016

Treatment with the BTK inhibitor BGB-3111 had an objective response rate of 96% for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

Acalabrutinib Safe, Effective in Ibrutinib-Intolerant CLL/SLL

December 6th 2016

The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).